Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

- Scientific Presentation at the 99th Annual Meeting of the American

Association for Cancer Research (AACR) -

TORONTO, April 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced presentations of further preclinical data from its two lead anticancer drugs at the Annual Meeting of the AACR in San Diego, CA, April 12-16, 2008.

The first presentation titled, "Preclinical development of LOR-253, a novel anticancer drug candidate that functions by modulating intracellular labile zinc homeostasis leading to cell cycle arrest," will be presented on April 16, 2008.

In this presentation, Lorus provided data on the preclinical development of LOR-253 (formerly known as LT-253), the Company's lead anticancer small molecule, with a novel cellular target. In animal studies, LOR-253 showed a favorable pharmacokinetic profile following intravenous dosing. A key finding of the study was the tissue distribution of LOR-253, where the drug was detected in tumor tissues in animal models, with significant affinity for lung and colon tissues. These results strongly support the potential treatment of these cancers with LOR-253, which has shown selective and potent anticancer activity in animal models of non-small cell lung cancer and colon cancer.

LOR-253 is currently in IND-enabling GLP toxicology studies, which are to be completed by mid-2008. Planning of a Phase I clinical trial in cancer indications for LOR-253 is in progress.

The second presentation, presented on April 13, 2008 titled, "GTI-2040 displays cooperative anti-tumor activity, when combined with chemotherapeutics and immunotherapeutics against human renal carcinoma xenografts".

This study reported preclinical results from combination therapies with
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... at Indiana University Bloomington have described the self-assembly ... development with potential value for the field of ... photovoltaic cells. , Their paper, "Anion-Induced Dimerization of ... 2D Self-Assembled Crystals," has been published online by ... Royal Society of Chemistry. It is the first ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® bearings ... are uniquely suited to prevent loss of lubrication that ... high temperatures . , Recently, a manufacturer of ... at Graphite Metallizing to overcome problems with movement of ... pans containing blocks of powder mixture are loaded onto ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading ... oncology, today announced that it will hold an investor ... Company's financial results for the first quarter of fiscal ... in the current fiscal year. , The dial-in number ... 14, 2014, at 5 p.m. EDT (2 p.m. PDT) ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... development and commercial supply agreement with Hospira ... business unit to manufacture clinical-grade Oxycyte(R). Oxycyte ... carrier. Oxycyte will be manufactured at Hospira,s ...
... on the 1918 Spanish Influenza Strain Protected Mice and ... Bird FluROCKVILLE, Md., April 14 ... NVAX ) today reported preclinical study results ... based on the 1918 Spanish influenza strain protected against ...
... - BioMS Medical Corp. (TSX: MS), a leading developer ... that the independent Data Safety Monitoring Board (DSMB) for ... dirucotide in patients with secondary progressive MS has completed ... as per the protocol. , This was the fourth ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... many of the roughly 156,000 gas stations across ... in parts of underground gas storage tankscorrosion that ... groundwater, a source of drinking water. In recent ... many rapidly corroding gas storage tank components such ... with use of gasoline-ethanol blends and the presence ...
(Date:7/31/2014)... Neb., July 31, 2014 -- Do people make a ... mothers raise them that way? Is it a matter ... Nebraska-Lincoln and a colleague from Rice University say that ... some people lean left while others lean right. , ... and deep-seated psychology are at the core of political ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3NIST corrosion lab tests suggest need for underground gas tank retrofits 2Scientists find growing consensus: Political attitudes derive from body and mind 2
... , SAN DIEGO, Dec. 10 ... of an existing building (Keen Hall), including a previously unused ... for the University of California, Riverside. Ken Kornberg, president ... project element was to ensure that although the facility was ...
... WASHINGTON, Dec. 10, 2009 Arup K. SenGupta, Ph.D., ... Lehigh University in Bethlehem, Pa., has been chosen to ... administered by the American Chemical Society, is given to ... improve public health through their work in the chemical ...
... the University of California, Riverside will receive more than $1 ... Antenna Research Center ( PARC ), to be headquartered at ... to better understand natural photosynthetic systems and design more durable ... cells during the past 15 years has failed to appreciably ...
Cached Biology News:Kornberg Associates | Architects Completes UC Riverside Stem Cell Core Facility Project 2Copying mother nature's designs 2
... Many differences exist between the various ... of glass slide used, the length and ... targets, and the manufacturing protocol employed all ... microarray analysis. With all the different ...
... Extraction Software reads and processes ... prepare microarray data for analysis. ... one 2-year license for ... accounts , * one ...
... The DMW143 taken from the SMZ line is ... of production and testing. It is available with ... (FBGG) or a space-saving compact base (N2GG). This ... TV and a projector all at the same ...
... The economical ICS-90 uses continuous chemical suppression ... give you fast, accurate determinations of common ... Easy to operate, quick to equilibrate, and ... compact ICS-90 helps you achieve maximum sample ...
Biology Products: